After TUR for superficial bladder cancer, intravesical epirubicin prophylaxis decreases recurrence rates compared with placebo or TUR alone. The drug can be used as a single dose or in an ...

We conducted a phase II study to assess the efficacy of combined epirubicin and paclitaxel as neoadjuvant therapy in women with locally advanced or high tumour-to-breast ratio breast cancer to ...